Opening book details…
About this nonfiction
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study by Cho, Byoung Chul (author);Abreu, Delvys Rodriguez (author);Hussein, Maen (author);Cobo, Manuel (author);Patel, Anjan J (author);Secen, Nevena (author);Lee, Ki Hyeong (author);Massuti, Bartomeu (author);Hiret, Sandrine (author);Yang, James Chih Hsin (author);Barlesi, Fabrice (author);Lee, Dae Ho (author);Ares, Luis Paz (author);Hsieh, Robert W (author);Patil, Namrata S (author);Twomey, Patrick (author);Yang, Xiaoying (author);Meng, Raymond (author);Johnson, Melissa L (author) is a nonfiction available to read on EtoBox.
It is typically read by self-directed learners exploring a subject in depth.
Common subject areas: history, science, philosophy, social sciences.
- Author
- Cho, Byoung Chul (author);Abreu, Delvys Rodriguez (author);Hussein, Maen (author);Cobo, Manuel (author);Patel, Anjan J (author);Secen, Nevena (author);Lee, Ki Hyeong (author);Massuti, Bartomeu (author);Hiret, Sandrine (author);Yang, James Chih Hsin (author);Barlesi, Fabrice (author);Lee, Dae Ho (author);Ares, Luis Paz (author);Hsieh, Robert W (author);Patil, Namrata S (author);Twomey, Patrick (author);Yang, Xiaoying (author);Meng, Raymond (author);Johnson, Melissa L (author)
- Publisher
- Elsevier BV
- Published
- 2022
- Language
- EN
- Category
- nonfiction
More by Cho, Byoung Chul (author);Abreu, Delvys Rodriguez (author);Hussein, Maen (author);Cobo, Manuel (author);Patel, Anjan J (author);Secen, Nevena (author);Lee, Ki Hyeong (author);Massuti, Bartomeu (author);Hiret, Sandrine (author);Yang, James Chih Hsin (author);Barlesi, Fabrice (author);Lee, Dae Ho (author);Ares, Luis Paz (author);Hsieh, Robert W (author);Patil, Namrata S (author);Twomey, Patrick (author);Yang, Xiaoying (author);Meng, Raymond (author);Johnson, Melissa L (author)
Similar books
- Ivonescimab Versus Pembrolizumab for PD-L1-positive Non-small Cell Lung Cancer (HARMONi-2): a Randomised, Double-blind, Phase 3 Study in China — Xiong, Anwen; Wang, Lei; Chen, Jianhua; Wu, Lin; Liu, Baogang; Yao, Jun; Zhong, Hua; Li, Jie; Cheng, Ying; Sun, Yulan; Ge, Hui; Yao, Jifang; Shi, Qin; Zhou, Ming; Chen, Bolin; Han, Zhengxiang; Wang, Jinliang; Bu, Qing; Zhao, Yanqiu; Chen, Junqiang; Nie, Ligong; Li, Gaofeng; Li, Xingya; Yu, Xinmin; Ji, Yinghua; Sun, Daqiang; Ai, Xiaohong; Chu, Qian; Lin, Yu; Hao, Jiqing; Huang, Dingzhi; Zhou, Chengzhi; Shan, Jinlu; Yang, Hongzhong; Liu, Xuewen; Wang, Jing; Shang, Yanhong; Mei, Xiaodong; Yang, Jie; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Zhou, Caicun (2025)
- Transarterial Chemoembolisation Combined with Lenvatinib Plus Pembrolizumab Versus Dual Placebo for Unresectable, Non-metastatic Hepatocellular Carcinoma (LEAP-012): a Multicentre, Randomised, Double-blind, Phase 3 Study — Kudo, Masatoshi; Ren, Zhenggang; Guo, Yabing; Han, Guohong; Lin, Hailan; Zheng, Jinfang; Ogasawara, Sadahisa; Kim, Ji Hoon; Zhao, Haitao; Li, Chuan; Madoff, David C; Ghobrial, R Mark; Kawaoka, Tomokazu; Gerolami, René; Ikeda, Masafumi; Kumada, Hiromitsu; El-Khoueiry, Anthony B; Vogel, Arndt; Peng, Xiang; Mody, Kalgi; Dutcus, Corina; Dubrovsky, Leonid; Siegel, Abby B; Finn, Richard S; Llovet, Josep M (2025)
- Candesartan Versus Placebo for Migraine Prevention in Patients with Episodic Migraine: a Randomised, Triple-blind, Placebo-controlled, Phase 2 Trial — Øie, Lise Rystad; Wergeland, Tore; Salvesen, Øyvind; Gravdahl, G⊘ril Bruvik; Aschehoug, Irina; Gulati, Sasha; Bj⊘rk, Marte-Helene; Lundqvist, Christofer; Alstadhaug, Karl Bj⊘rnar; Winsvold, Bendik Slagsvold; Aamodt, Anne Hege; Larsen, Iben Cornelia; B⊘e, Magne Geir; Braschinsky, Mark; Müller, Bernd; Vetvik, Kjersti Gr⊘tta; Müller, Kai Ivar; Aaseth, Kjersti; Khanevski, Andrej Netland; Øvrevik, Ane Bakke; Vegrim, Håkon Magne; Lindroos, Jenny; Eid, Karine; Engstrand, Helene; Bezgal, Burcu; Larsen, Martha Brakestad; Østhus, Joakim H⊘gsteggen; Stovner, Lars Jacob; Tronvik, Erling (2025)
- First-line Serplulimab or Placebo Plus Chemotherapy in PD-L1-positive Esophageal Squamous Cell Carcinoma: a Randomized, Double-blind Phase 3 Trial — Yan Song & Bo Zhang & Dao Xin & Xiaoge Kou & Zhenbo Tan & Shu Zhang & Meili Sun & Jin Zhou & Min Fan & Ming Zhang & Yongxiang Song & Suyi Li & Yuan & Wu Zhuang & Jingdong Zhang & Li Zhang & Hao Jiang & Kangsheng Gu & Huangyang Ye & Ying Ke & Jing... (2023)
- Naltrexone 6 Mg Once Daily Versus Placebo in Women with Fibromyalgia: a Randomised, Double-blind, Placebo-controlled Trial — Due Bruun, Karin; Christensen, Robin; Amris, Kirstine; Vaegter, Henrik Bjarke; Blichfeldt-Eckhardt, Morten Rune; Bye-Møller, Lars; Holsgaard-Larsen, Anders; Toft, Palle (2023)
- Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel for Second-line Treatment of Stage IV Non-small-cell Lung Cancer After Disease Progression on Platinum-based Therapy (REVEL): a Multicentre, Double-blind, Randomised Phase 3 Trial — Edward B Garon; Tudor-Eliade Ciuleanu; Oscar Arrieta; Kumar Prabhash; Konstantinos N Syrigos; Tuncay Goksel; Keunchil Park; Vera Gorbunova; Ruben Dario Kowalyszyn; Joanna Pikiel; Grzegorz Czyzewicz; Sergey V Orlov; Conrad R Lewanski; Michael Thomas; Paolo Bidoli; Shaker Dakhil; Steven Gans; Joo-Hang Kim; Alexandru Grigorescu; Nina Karaseva; Martin Reck; Federico Cappuzzo; Ekaterine Alexandris; Andreas Sashegyi; Sergey Yurasov; Maurice Pérol (2014)